Bioventus LLC12.05.16
Bioventus, a provider of orthobiologics, has announced that a published study reveals its latest generation Exogen Ultrasound Bone Healing System improves patient compliance by 10 percent and overall compliance never fell below 76 percent. Exogen uses safe, effective low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural healing process.1 The findings are published in the November 30, 2016 issue of Medical Devices: Evidence and Research available here.
The next generation Exogen device launched in 2014 and features a compliance calendar. The study found that among 12,984 patient data files analyzed, the patient compliance was 84 percent, while compliance with the previous generation Exogen device was 74 percent. In addition, incorporation of the calendar feature resulted in compliance never decreasing below 76 percent over the six-month analysis period.
The researchers also analyzed 12 clinical trials on LIPUS where compliance was recorded. In eight of these clinical studies, where they met their end point, compliance was 88 percent. If the primary end point was unmet, compliance averaged 54 percent.
“This study clearly shows a correlation between clinical effectiveness and compliance rates of more than 70 percent,” said Neill Pounder, director—project management, Bioventus. “The work also revealed that use of the next generation Exogen device resulted in a measurable improvement in patient adherence, which may help to optimize clinical outcomes and fracture healing. LIPUS technology can make a difference if it used as directed.”
Authors of this study are N.M. Pounder, J.T Jones and K.J. Tanis of Bioventus.
Reference
1 Azuma Y, Ito M, Harada Y, Takagi H, Ohta T, Jingushi S. Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus. J Bone Miner Res. 2001; 16(4):671-680.
The next generation Exogen device launched in 2014 and features a compliance calendar. The study found that among 12,984 patient data files analyzed, the patient compliance was 84 percent, while compliance with the previous generation Exogen device was 74 percent. In addition, incorporation of the calendar feature resulted in compliance never decreasing below 76 percent over the six-month analysis period.
The researchers also analyzed 12 clinical trials on LIPUS where compliance was recorded. In eight of these clinical studies, where they met their end point, compliance was 88 percent. If the primary end point was unmet, compliance averaged 54 percent.
“This study clearly shows a correlation between clinical effectiveness and compliance rates of more than 70 percent,” said Neill Pounder, director—project management, Bioventus. “The work also revealed that use of the next generation Exogen device resulted in a measurable improvement in patient adherence, which may help to optimize clinical outcomes and fracture healing. LIPUS technology can make a difference if it used as directed.”
Authors of this study are N.M. Pounder, J.T Jones and K.J. Tanis of Bioventus.
Reference
1 Azuma Y, Ito M, Harada Y, Takagi H, Ohta T, Jingushi S. Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus. J Bone Miner Res. 2001; 16(4):671-680.